After losses and mistrials this year in its talc defense, Johnson & Johnson has scored a second straight win in a mesothelioma case in California.
Merck kicked off a rolling FDA submission for its Ebola vaccine that's already been deployed against outbreaks in the Democratic Republic of Congo.
With I-O drug development continually changing, an understanding of clinical biomarker testing is needed now more than ever.
Pfizer launched its third biosim, Retacrit, at a significant discount to anemia drugs from Amgen and Johnson & Johnson.
Korean securities watchdog has requested to review whether the company should be delisted and recommended the dismissal of its CEO.
Could an FDA-approved digital pill that communicates with your mobile phone upend healthcare? A new Executive Insights explains.
Pfizer has come up short in a long-running patent battle in the U.K. over its blockbuster Lyrica, potentially costing the drugmaker.
Novartis once estimated a spinoff of its eye-care unit Alcon could be worth up to $35 billion, but it's facing some challenges.
Who wants drug prices in ads? Older people, that’s who.
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.
Mitsubishi Tanabe Pharma is looking for ALS stories. Not patient stories, but rather the stories—and art and video creations—of teen caregivers.
Johnson & Johnson's Janssen is using Twitter to get the word out about the link between Type 2 diabetes and cardiovascular risks.
